Systematic review of proposed inflammatory mechanisms by which patients with psoriasis are considered at greater risk of cardiovascular disease | [Journal of Pakistan Association of Dermatologists • 2024]

Author(s):

1. Sana Mughal: Department of Dermatology, Isra University Hospital, Hyderabad.Pakistan

2. Yasmeen Fatima: Jinnah University for Women, Karachi, Pakistan

Abstract:

Systemic literature review on proposed inflammatory mechanisms by which patients with psoriasis are considered at greater risk of cardiovascular disease. A thorough search of the scientific literature on quality of life impairment in psoriasis patients from January 1, 1998, to Dec 30, 2018, was done using the electronic databases PubMed, EMBASE, NIH and Web of Science. Studies were included in accordance with the selection criteria. The survey did not include any editorials, letters to the editor, or commentaries. To repeat, these experimentations have provided evidence of association of cardiovascular comorbidity risk in the patients of psoriasis with the concept of numerous inflammatory pathways linked to one another. To summarize, the leading processes proposed to be correlating these two diseases, includes vascular inflammation, oxidative stress and dyslipidemia, inflammatory cytokines, overexpression of inflammatory genes, inflamed adipocytes, and a hypothesis of psoriatic march, role of numerous biomarkers etc. Future studies should be carried in consideration of treatment regimens to decrease the disease burden of comorbidities, as well as improve the quality of life of patients of psoriasis.

Page(s): 235-242

DOI: DOI not available

Published: Journal: Journal of Pakistan Association of Dermatologists, Volume: 34, Issue: 1, Year: 2024

Keywords:

Psoriasis , Cardiovascular disease , Inflammatory , Abstract

References:

[1] Takeshita J.,Grewal S.,Langan S. M.,Mehta N. N.,Ogdie A.,Van Voorhees A. S.,Gelfand J. M. .2017 .Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol, 76(3) : 377-90.

[2] Capon F.,Burden A.D.,Trembath R.C.,Barker J.N. .2011 .Psoriasis and other complex trait dermatoses: From loci to functional pathways. J Investig Dermatol, 132(3) : 915-22.

[3] Deng Y.,Scherer P. E. .2010 .Adipokines as novel biomarkers and regulators of the metabolic syndrome. Annals of the New York Acad Sci, 1212(1) : E1-E19.

[4] Bø K.,Thoresen M.,Dalgard F. .2008 .Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults. Dermatology, 216(1) : 40-5.

[5] .2014 .(Video) Janssen Pharmaceutical Companies of Johnson & Johnson. A Nature research Journal. , : .

[6] Furue M.,Tsuji G.,Chiba T.,Kadono T. .2017 .Cardiovascular and metabolic diseases comorbid with psoriasis: Beyond the skin. Internal Medicine, 56(13) : 1613-9.

[7] Gelfand J. M.,Neimann A. L.,Shin D.B.,Wang X.,Margolis D. J.,Troxel A. B. .2006 .Risk of myocardial infarction in patients with psoriasis. JAMA, 296(14) : 1735-41.

[8] Papadavid E.,Diamanti K.,Spathis A.,Varoudi M.,Andreadou I.,Gravanis K.,Ikonomidis I. .2016 .Increased levels of circulating platelet-derived microparticles in psoriasis: Possible implications for the associated cardiovascular risk. World J Cardiol, 8(11) : 667.

[9] Chandrashekar L.,Rajappa M.,Revathy G.,Sundar I.,Munisamy M.,Ananthanarayanan P. H,Basu D. .2015 .Is enhanced platelet activation the missing link leading to increased cardiovascular risk in psoriasis?. Clinica Chimica Acta, 446 : 181-5.

[10] Nielsen H. J.,Christensen I. J.,Svendsen N.,Hansen U.,Werther K.,Brünner N.,Kristensen J. K. .2002 .Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res, 51(11) : 563-7.

[11] Erturan ,Köroğlu B. K.,Adiloğlu A.,Ceyhan A. M.,Akkaya V. B.,Tamer N.,Kılınç O. .2014 .Evaluation of serum s CD 40 L and homocysteine levels with subclinical atherosclerosis indicators in patients with psoriasis: a pilot study. Int J Dermatol, 53(4) : 503-9.

[12] Gerdes S.,Osadtschy S.,Buhles N.,Baurecht H.,Mrowietz U. .2014 .Cardiovascular biomarkers in patients with psoriasis. Exp Dermatol, 23(5) : 322-5.

[13] Takahashi H.,Iinuma S.,Honma M.,Iizuka H. .2014 .Increased serum C reactive protein level in Japanese patients of psoriasis with cardio and cerebrovascular disease. J Dermatol, 41(11) : 981-5.

[14] Baran A.,Myśliwiec H.,Kiluk M.,Świderska P.,Flisiak M.,I. M. .2018 .Serum YKL-40 as a potential biomarker of inflammation in psoriasis. J Dermatol Treat, 29(1) : 19-23.

[15] Torres T.,Bettencourt N.,Mendonça D.,Vasconcelos C.,Silva B. M.,Selores M. Complement .2014 .C3 as a marker of cardiometabolic risk in psoriasis. Arch Dermatol Res, 306(7) : 653-60.

[16] Boehncke W. H.,Boehncke S.,Tobin A. M.,Kirby B. .2011 .The „psoriatic march‟: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol, 20(4) : 303-7.

[17] Malecic N.,Young H. S. .2017 .Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia. Exp Dermatol, 26(4) : 299-304.

[18] Mehta N. N.,Li K.,Szapary P.,Krueger J.,Brodmerkel C. .2013 .Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. J Trans Med, 11(1) : 194.

[19] He F.,Zuo L. .2015 .Redox roles of reactive oxygen species in cardiovascular diseases. Int J Mol Sci, 16(11) : 27770-80.

[20] Ghazizadeh R.,Shimizu H.,Tosa M.,Ghazizadeh M. .2010 .Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci, 7(5) : 284-9.

[21] Xu J.,Lu X.,Shi G. P. .2015 .Vasa vasorum in atherosclerosis and clinical significance. Int J Mol Sci, 16(5) : 11574-608.

[22] Furuhashi T.,Saito C.,Torii K.,Nishida E.,Yamazaki S.,Morita A. .2013 .Photo (chemo) therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis. PLoS One, 8(1) : e54895.

[23] Youn S. W.,Kang S. Y.,Kim S. A.,Park G. Y.,Lee W. W. .2015 .Subclinical systemic and vascular inflammation detected by 18F fluorodeoxyglucose positron emission tomography/computed tomography in patients with mild psoriasis. J Dermatol, 42(6) : 559-66.

[24] Hjuler K. F.,Gormsen L. C.,Vendelbo H.,Egeberg A.,Nielsen J.,Iversen L. .2017 .Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate to severe psoriasis. Br J Dermatol, 176(3) : 732-40.

[25] Griffiths C. E. M.,Van der Walt J. M.,Ashcroft D. M.,Flohr C.,Naldi L.,Nijsten T.,Augustin M. .2017 .The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol, 177(1) : e4-e7.

[26] Davidovici B. B.,Sattar N.,Jörg P. C.,Puig L.,Emery P.,Barker J. N.,Krueger J. G. .2010 .Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol, 130(7) : 1785-96.

[27] Rachakonda ,Schupp C. W.,Armstrong A. W. .2014 .Psoriasis prevalence among adults in the United States. J Am Acad of Dermatol, 70(3) : 512-6.

[28] Danielsen K.,Olsen A. O.,Wilsgaard T.,Furberg A. S. Is .2013 .the prevalence of psoriasis increasing? A 30 year follow up of a population based cohort. Br J Dermatol, 168(6) : 1303-10.

[29] Stern R. S.,Nijsten T.,Feldman S. R.,Margolis D. J.,Rolstad T. .2004 .Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Sympos Proceed, 9(2) : 136-9.

[30] Kurd S. K.,Gelfand J. M. .2009 .The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad of Dermatol, 60(2) : 218-24.

[31] Gelfand J. M.,Weinstein R.,Porter S. B.,Neimann A. L.,Margolis J. A.,D. J. Prevalence J. A. .2005 .and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol, 141(12) : 1537-41.

[32] Michalek I. M.,Loring B.,John S. M. .2017 .A systematic review of worldwide epidemiology of psoriasis. J Eur Acad of Dermatol Venereol, 31(2) : 205-12.

[33] Parisi R.,Symmons D. P.,Griffiths C. E.,Ashcroft D. M. .2013 .Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol, 133(2) : 377-85.

[34] .2016 .. Global report on psoriasis., : .

[35] Joshi A.,Lerman J.,Dey A.,Sajja A.,Belur A.,Elnabawi Y. .2018 .Association Between Aortic Vascular Inflammation and Coronary Artery Plaque Characteristics in Psoriasis. JAMA Cardiol, 3(10) : 949.

[36] Sorokin A. V.,Kotani K.,Elnabawi Y. A.,Dey A. K.,Sajja A. P.,Yamada S.,Gelfand J. M. .2018 .Association between oxidation-modified lipoproteins and coronary plaque in psoriasis: an observational cohort study. Circul Res, 123(11) : 1244-54.

[37] Hu S.,Lan C. C. E. .2017 .Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci, 18(10) : 2211.

[38] Holzer M.,Wolf P.,Curcic S.,Weger BirnerGruenberger,Inzinger W.,Marsche M.,G. M. .2012 .Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res, 53(8) : 1618-24.

[39] Armstrong E. J.,Krueger J. G. .2016 .Lipoprotein metabolism and inflammation in patients with psoriasis. Am J Cardiol, 118(4) : 603-9.

[40] Shahwan K.,Kimball A.,Psoriasis Cardiovascular,Disease Cardiovascular .2015 .. Medical Clinics of North America, 99(6) : 1227-42.

Citations

Downloads

Views